Abcam, ab137015, Anti-CYP2C19 antibody [EPR6576]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal CP2CJ antibody. Suitable for WB, IHC-P and reacts with Mouse, Rat, Human samples. Cited in 17 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR6576,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody is very likely to be cross-reactive with many Cytochrome P450 family members. According to the blast result, in human species, the immunogen has 100% homology with CYP2C9, CYP2A6 and CYP2A7, 85.7% with CYP2C18, 78.6% with CYP2A13 and CYP2C8. CYP2C19 doesn`t exist in mouse and rat species. The immunogen shares 100% homology with mouse CYP2A4, CYP2A5, CYP2A12, CYP2C29, CYP2C70 and rat CYP2A3, CYP2C6, CYP2C55, 92.9% with mouse CYP2C37, CYP2C50, CYP2C55 and rat CYP2C11, CYP2C13.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CYP2C19 also referred to as cytochrome P450 2C19 is an enzyme that belongs to the cytochrome P450 superfamily. This protein has a molecular mass of approximately 56 kDa. CYP2C19 is primarily expressed in the liver but also appears in the intestine. The enzyme plays a significant mechanical role in the oxidative metabolism of various substrates including both endogenous compounds and exogenous drugs. The chemical reactions it facilitates involve the oxidation of organic substances.
Biological function summary
Cytochrome P450 2C19 is responsible for metabolizing drugs such as proton pump inhibitors antiepileptic drugs and some antidepressants. This enzyme is part of a larger enzyme family that contributes to the detoxification processes and biosynthesis of steroid hormones. It acts by catalyzing the oxidative transformation of compounds which influences drug activation and clearance. Its substrate specificity includes many significant pharmacological agents.
Pathways
CYP2C19 is integrally involved in drug metabolism pathways particularly the Phase I metabolism. It cooperates with enzymes like CYP2C9 and CYP3A4 within these pathways performing hydrolytic and oxidative reactions that transform lipophilic drugs into more water-soluble derivatives. Consequently this activity prepares compounds for further modification in Phase II metabolism facilitating excretion from the body.
CYP2C19 is implicated in conditions such as cardiovascular disease and adverse drug reactions. Genetic polymorphisms within the CYP2C19 gene lead to varied metabolic capacities affecting the efficacy and safety of therapeutics especially antiplatelet drugs like clopidogrel. Additionally alterations in CYP2C19 activity are associated with altered drug metabolism which may result in interactions with proteins such as P-glycoprotein and other cytochrome P450 enzymes affecting therapeutic outcomes.